Skip to main content
SpringerLink
Log in

Parkinsonian Drugs: Indications

  • Living reference work entry
  • First Online:
NeuroPsychopharmacotherapy

Abstract

Many substance classes have been introduced for the treatment of motor symptoms in Parkinson’s disease within the last 50 years. The most important and effective medication is still levodopa in combination with a decarboxylase inhibitor. In addition, dopamine agonists, monoamine oxidase B (MAO-B) inhibitors, catechol-o-methyltransferase (COMT) inhibitors, amantadine (N-methyl-d-aspartate-antagonist), and less important anticholinergics are administered depending on the motor symptoms, age, and a multitude of other factors. Fortunately, within the substance classes there are various preparations, which also have different effects. In order that the advantages of the individual medications can be exploited and undesired effects and interactions can be avoided, one must come to terms with the complex data and the pharmacology of the medication. In addition, important aspects are interactions and reciprocal actions. The decision as to which medication to choose must be made individually for each patient.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Anonymous. Anticholinergic therapies in the treatment of Parkinson’s disease. Mov Disord. 2002;17:S7–12.

    Article  Google Scholar 

  • Assal F, Spahr L, Hadengue A, Rubbia-Brandt L, Burkhard PR. Tolcapone and fulminant hepatitis. Lancet. 1998;352(9132):958.

    Article  CAS  PubMed  Google Scholar 

  • Axelrod J, Tomchick R. Enzymatic O-methylation of epinephrine and other catechols. J Biol Chem. 1958;233:702–5.

    CAS  PubMed  Google Scholar 

  • Baas H, Zehrden F, Selzer R, Kohnen R, Loetsch J, Harder S. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson’s disease. Clin Pharmacokinet. 2001;40:383–93.

    Article  CAS  PubMed  Google Scholar 

  • Barbeau A, Sourkes TL, Murphy GF. Les catecholamines dans la maladie de Parkinson. In: De Ajuriaguerra J, editor. Monoamines et système nerveux central. Paris: Masson; 1962. p. 247–62.

    Google Scholar 

  • Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, Weintraub D. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:573–80.

    Article  CAS  PubMed  Google Scholar 

  • Biglan KM, Holloway RG. A review of pramipexole and its clinical utility in Parkinson’s disease. Expert Opin Pharmacother. 2002;3:197–210.

    Article  CAS  PubMed  Google Scholar 

  • Birkmayer W, Hornykiewicz O. Der l-3,4-Dioxyphenylalanin (=DOPA)-Effekt bei der Parkinson-Akinesie. Wien Klin Wochenschr. 1961;73:787–8.

    CAS  PubMed  Google Scholar 

  • Birkmayer W, Riederer P, Youdim MB, Linauer W. The potentiation of the antiakinetic effect after l-dopa treatment by an inhibitor of MAO-B, deprenyl. J Neural Transm. 1975;36:303–26.

    Article  CAS  PubMed  Google Scholar 

  • Bonifácio MJ, Palma PN, Almeida L, Soares-da-Silve P. Catechol-O-methyltransferase and its inhibitors in Parkinson’s disease. CNS Drug Rev. 2007;13:352–79.

    Article  PubMed  PubMed Central  Google Scholar 

  • Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R. Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord. 2014a;29:229–37.

    Article  CAS  PubMed  Google Scholar 

  • Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt MH, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord. 2014b;29:1273–80.

    Article  CAS  PubMed  Google Scholar 

  • Brecht HM. Dopaminagonisten im Vergleich. In: Riederer P, Laux G, Pöldinger W, editors. Neuro-Psycho-pharmaka, vol. 5. Wien/New York: Springer; 1992. p. 226–40.

    Google Scholar 

  • Castro-Caldas A, Delwaide P, Jost W, Merello M, Williams A, Lamberti P, Aguilar M, Del Signore S, Cesaro P. The Parkinson-control study: a 1-year, randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with l-dopa in Parkinson’s disease. Mov Disord. 2006;21:500–9.

    Article  PubMed  Google Scholar 

  • Cattaneo C, Ferla RL, Bonizzoni E, Sardina M. Long-term effects of safinamide on dyskinesia in mid- to late stage Parkinson’s disease: a post-hoc analysis. J Parkinsons Dis. 2015;5:475–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cedarbaum JM. The promise and limitations of controlled-release oral levodopa administration. Clin Neuropharmacol. 1989;12:147–66.

    Article  CAS  PubMed  Google Scholar 

  • Corsini GU, Del Zompo M, Gessa GL, Mangoni A. Therapeutic efficacy of apomorphin combined with an extracerebral inhibitor of dopamine receptors in Parkinson’s disease. Lancet. 1979; 1(8123):954–6.

    Article  CAS  PubMed  Google Scholar 

  • Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med. 1967;276(7):374–9.

    Article  CAS  PubMed  Google Scholar 

  • Dashtipour K, Chen JJ, Kani C, Bahjri K, Ghamsary M. Clinical outcomes in patients with Parkinson’s disease treated with a monoamine oxidase type-B inhibitor: a cross-sectional, cohort study. Pharmacotherapy. 2015;35:681–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Del Dotto P, Pavese N, Cambaccini G, Bernardini S, Metman LV, Chase TN, Bonuccelli U. Intravenous amantadine improves levodopa induced dyskinesias: an acute double-blind placebo controlled study. Mov Disord. 2001;16:515–20.

    Article  PubMed  Google Scholar 

  • DGN. S3-Leitlinie Idiopathisches Parkinson-Syndrom. 2016. http://www.dgn.org/images/red_leitlinien/LL_2016/PDFs_Download/030010_LL_kurzfassung_ips_2016.pdf

  • Dooley M, Markham A. Pramipexole. Drugs Aging. 1998;12:495–514.

    Article  CAS  PubMed  Google Scholar 

  • Eggert KM, Oertel WH, Reichmann H. Parkinson-Syndrome: Diagnostik und Therapie. In: Diener HC, Weimar C, et al., editors. Leitlinien fĂĽr Diagnostik und Therapie in der Neurologie. 5th ed. Stuttgart: Thieme-Verlag; 2012. p. 124–62.

    Google Scholar 

  • Eggert K, Ă–hlwein C, Kassubek J, Wolz M, Kupsch A, Ceballos-Baumann A, Ehret R, Polzer U, Klostermann F, Schwarz J, Fuchs G, Jost W, Albert A, Haag A, Hermsen A, LohmĂĽller K, Kuhn K, Wangemann M, Oertel WH. Influence of the non-ergot dopamine agonist piribedil on vigilance in patients with Parkinson disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole. Clin Neuropharmacol. 2014;37:116–22.

    Article  CAS  PubMed  Google Scholar 

  • Factor SA. Intermitent subcutaneous apomorphine therapy in Parkinson’s disease. Neurology. 2004;62(Suppl 4):S12–7.

    Article  CAS  PubMed  Google Scholar 

  • Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K, Parkinson Study Group. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351:2498–508.

    Article  CAS  PubMed  Google Scholar 

  • Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Mov Disord. 2015;30:500–9.

    Article  CAS  PubMed  Google Scholar 

  • Ferrara JM, Stacy M. Impulse-control disorders in Parkinson’s disease. CNS Spectr. 2008; 13:690–8.

    Article  PubMed  Google Scholar 

  • Ferreira JJ, Rocha JF, FalcĂŁo A, Santos A, Pinto R, Nunes T, Soares-da-Silva P. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson’s disease. Eur J Neurol. 2015;22:815–25.

    Article  CAS  PubMed  Google Scholar 

  • Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15:154–65.

    Article  CAS  PubMed  Google Scholar 

  • Finberg JPM, Lamersdorf I, Commissiong JW, Youdim MBH. Pharmacology and neuroprotective properties of rasagiline. J Neural Transm Suppl. 1996;48:95–101.

    CAS  PubMed  Google Scholar 

  • Fowler JS, MacGregor RR, Wolf AP, Arnett CD, Dewey SL, Schlyer D, Christman D, Logan J, Smith M, Sachs H. Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and positron emission tomography. Science. 1987;235:481–5.

    Article  CAS  PubMed  Google Scholar 

  • Fowler JS, Volkow ND, Logan J, Wang GJ, MacGregor RR, Schyler D, Wolf AP, Pappas N, Alexoff D, Shea C. Slow recovery of human brain MAO after l-deprenyl (selegiline) withdrawal. Synapse. 1994;18:86–93.

    Article  CAS  PubMed  Google Scholar 

  • Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2018; 33(8):1248–66.

    Article  CAS  PubMed  Google Scholar 

  • Fox SH, Katzenschlager R, Lim S-Y, Ravina B, Seppi K, Coelho M, Poewe W, Rascol O, Goetz CG, Sampaio C. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(Suppl 3): S2–41.

    Article  PubMed  Google Scholar 

  • Gouraud A, Millaret A, Descotes J, Vial T, French Association of Regional Pharmacovigilance Centres. Piribedil-induced sleep attacks in patients without Parkinson disease: a case series. Clin Neuropharmacol. 2011;34:104–7.

    Article  CAS  PubMed  Google Scholar 

  • GĂĽldenpfennig WM, Poole KH, Sommerville KW. Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin Neuropharamcol. 2005;28:106–10.

    Article  Google Scholar 

  • Hauser RA, Schapira AH, Rascol O, Barone P, Mizuno Y, Salin L, Haaksma M, Juhel N, Poewe W. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson’s disease. Mov Disord. 2010;25:2542–9.

    Article  PubMed  Google Scholar 

  • Hauser RA, Abler V, Eyal E, Eliaz RE. Efficacy of rasagiline in early Parkinson’s disease: a meta-analysis of data from the TEMPO and ADAGIO studies. Int J Neurosci. 2016;126:942–6.

    Article  CAS  PubMed  Google Scholar 

  • Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. 1967;17: 427–42.

    Article  CAS  PubMed  Google Scholar 

  • Jankovic J, Berkovich E, Eyal E, Tolosa E. Symptomatic efficacy of rasagiline monotherapy in early Parkinson’s disease: post-hoc analyses from the ADAGIO trial. Parkinsonism Relat Disord. 2014;20:640–3.

    Article  PubMed  Google Scholar 

  • Jorga K, Fotteler B, Schmitt M, Nielsen T, ZĂĽrcher G, Aitken J. The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations. Eur Neurol. 1997;38:59–67.

    Article  CAS  PubMed  Google Scholar 

  • Jost WH. Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration. Expert Opin Drug Saf. 2014;13:447–58.

    Article  CAS  PubMed  Google Scholar 

  • Jost WH, BrĂĽck C. Drug interactions in the treatment of Parkinson’s disease. J Neurol. 2002; 249(Suppl 3):24–9.

    CAS  Google Scholar 

  • Jost WH, Angersbach D, Rascol O. Clinical studies with ropinirole in Parkinson’s disease and RLS. J Neurol. 2006;253(Suppl 4):IV16–21.

    Article  PubMed  CAS  Google Scholar 

  • Jost WH, Klasser M, Reichmann H. Rasagilin im klinischen Alltag. Fortschr Neurol Psychiatr. 2008a;76:594–9.

    Article  CAS  PubMed  Google Scholar 

  • Jost WH, Kuhn K, Wangemann M. Piribedil: ein neuer, bekannter Dopaminagonist. Psychopharmakotherapie. 2008b;15:102–9.

    Google Scholar 

  • Jost W, Retzow A, Kuhn K. Piribedil – ein non-ergot Dopaminagonist mit besonderem Rezeptorprofil. Ergebnisse von zwei Studien bei Patienten mit idiopathischem Parkinsonsyndrom im klinischen Alltag. Nervenheilkunde. 2010;29:571–7.

    Article  Google Scholar 

  • Jost WH, Friede M, Schnitker J. Indirect meta-analysis of randomised placebo-controlled clinical trials on rasagiline and selegiline in the symptomatic treatment of Parkinson’s disease. Basal Ganglia. 2012;2:S17–26.

    Article  Google Scholar 

  • Kapp W. The history of drugs for the treatment of Parkinson’s disease. J Neural Transm Suppl. 1992;38:1–6.

    CAS  PubMed  Google Scholar 

  • Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database Syst Rev. 2003; CD003735.

    Google Scholar 

  • Keating GM, Lyseng-Williamson KA. Tolcapone: a review of its use in the management of Parkinson’s disease. CNS Drugs. 2005;19:165–84.

    Article  CAS  PubMed  Google Scholar 

  • Korczyn AD, Reichmann H, Boroojerdi B, Häck HJ. Rotigotine transdermal system for perioperative administration. J Neural Transm. 2007;114:219–21.

    Article  CAS  PubMed  Google Scholar 

  • Kvernmo T, Härtter S, BĂĽrger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther. 2006;28:1065–78.

    Article  CAS  PubMed  Google Scholar 

  • Lebrun-Frenay C, Borg M. Choosing the right dopamine agonist for patients with Parkinson’s disease. Curr Med Res Opin. 2002;18:209–14.

    Article  CAS  PubMed  Google Scholar 

  • Lees AJ. Levodopa substitution: the gold standard. Clin Neuropharmacol. 1994;17:1–6.

    Article  Google Scholar 

  • Lees AJ, Ratziu V, Tolosa E, Oertel WH. Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78:944–8.

    Article  CAS  PubMed  Google Scholar 

  • Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, Soares-da-Silva P. Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 2017;74:197–206.

    Article  PubMed  Google Scholar 

  • Lew MF, Kricorian G. Results from a 2-year centralized tolcapone liver enzyme monitoring program. Clin Neuropharmacol. 2007;30(5):281–6.

    Article  CAS  PubMed  Google Scholar 

  • Lew MF, Hauser RA, Hurtig HI, Ondo WG, Wojcieszek J, Goren T, Fitzer-Attas CJ. Long-term efficacy of rasagiline in early Parkinson’s disease. Int J Neurosci. 2010;120:404–8.

    Article  CAS  PubMed  Google Scholar 

  • Lewitt PA, Boroojerdi B, Surmann E, Poewe W. Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER. J Neural Transm. 2013;120:1069–81.

    Article  CAS  PubMed  Google Scholar 

  • Linazasoro G, Grandas F, Martinez Martin P, Bravo JL. Controlled release levodopa in Parkinson’s disease: influence of selection criteria and conversion recommendations in the clinical outcome of 450 patients. Clin Neuropharmacol. 1999;22:74–9.

    Article  CAS  PubMed  Google Scholar 

  • Männistö PT, Kaakkola S. Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson’s disease. Pharmacol Toxicol. 1990;66:317–23.

    Article  PubMed  Google Scholar 

  • Marzo A, Dal Bo L, Monti NC, Crivelli F, Ismaili S, Caccia C, Cattaneo C, Fariello RG. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res. 2004;50:77–85.

    Article  CAS  PubMed  Google Scholar 

  • Mazzio E, Deiab S, Park K, Soliman KF. High throughput screening to identify natural human monoamine oxidase B inhibitors. Phytother Res. 2013;27:818–28.

    Article  CAS  PubMed  Google Scholar 

  • Metman VL, Hoff J, Mouradian MM, Chase TN. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Mov Disord. 1994;9:463–5.

    Article  CAS  PubMed  Google Scholar 

  • Metman VL, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology. 1998;50:1323–6.

    Article  CAS  Google Scholar 

  • Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa-induced dyskinesias – a 1 year follow-up study. Arch Neurol. 1999;56:1383–6.

    Article  CAS  PubMed  Google Scholar 

  • Metman LV, Gillespie M, Farmer C, Bibbiani F, Konitsiotis S, Morris M, Shill H, Bara-Jimenez W, Mouradian MM, Chase TN. Continuous transdermal dopaminergic stimulation in advanced Parkinson’s disease. Clin Neuropharmacol. 2001;24:163–9.

    Article  CAS  PubMed  Google Scholar 

  • Möller JC, Oertel WH, Köster J, Pezzoli G, Provinciali L. Long-term efficacy and safety of pramipexole in advanced Parkinson’s disease: results from a European multicenter trial. Mov Disord. 2005;20:602–10.

    Article  PubMed  Google Scholar 

  • MĂĽller T, Kuhn W, Przuntek H. Efficacy of budipine and placebo in untreated patients with Parkinson’s disease. J Neural Transm. 2005;112:1015–23.

    Article  PubMed  CAS  Google Scholar 

  • MĂĽller T, Hoffmann JA, Dimpfel W, Oehlwein C. Switch from selegiline to rasagiline is beneficial in patients with Parkinson’s disease. J Neural Transm. 2013;120:761–5.

    Article  PubMed  CAS  Google Scholar 

  • Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson’s disease – long-term experience. Acta Neurol Scand. 2001;104:343–8.

    Article  CAS  PubMed  Google Scholar 

  • Nutt JG. Effects of catechol-O-methyltransferase (COMT) inhibition on the pharmacokinetics of l-dopa. Adv Neurol. 1996;69:493–6.

    CAS  PubMed  Google Scholar 

  • Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol. 1984;7:35–49.

    Article  CAS  PubMed  Google Scholar 

  • Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The “on-off” phenomenon in Parkinson’s disease: relation to absorption and transport. N Engl J Med. 1984;310:483–8.

    Article  CAS  PubMed  Google Scholar 

  • Nutt JG, Woodward WR, Gancher ST, Merrick D. 3-O-methyldopa and the response to levodopa in Parkinson’s disease. Ann Neurol. 1987;21:584–8.

    Article  CAS  PubMed  Google Scholar 

  • Obeso JA, Grandas F, Vaamonde J, Luquin MR, Artieda J, Lera G, Rodriguez ME, Martinez-Lage JM. Motor complications associated with chronic levodopa therapy in Parkinson’s disease. Neurology. 1989;39(Suppl 2):11–9.

    CAS  PubMed  Google Scholar 

  • Oertel W, Schulz JB. Current and experimental treatments of Parkinson disease: a guide for neuroscientists. J Neurochem. 2016;139(Suppl 1):325–37.

    Article  CAS  PubMed  Google Scholar 

  • Olanow CW, Stocchi F. Safinamide – a new therapeutic option to address motor symptoms and motor complications in mid- to late-stage Parkinson’s disease. Eur Neurol Rev. 2016; 11(Suppl 2):2–15.

    Google Scholar 

  • Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, Vanagunas A, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomized, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13:141–9.

    Article  CAS  PubMed  Google Scholar 

  • Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, Dellapina E, DestĂ©e A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology. 2014;82:300–7.

    Article  CAS  PubMed  Google Scholar 

  • Paci C, Thomas A, Onofrj M. Amantadine for dyskinesia in patients affected by severe Parkinson’s disease. Neurol Sci. 2001;22:75–6.

    Article  CAS  PubMed  Google Scholar 

  • PĂĄlhagen S, Heinonen E, Hägglund J, Kaugesaar T, Mäki-Ikola O, Palm R. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology. 2006;66:1200–6.

    Article  PubMed  Google Scholar 

  • Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease. JAMA. 2000;284:1931–8.

    Article  Google Scholar 

  • Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease. The TEMPO study. Arch Neurol. 2002;59:1937–43.

    Article  Google Scholar 

  • Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch Neurol. 2003;60:1721–8.

    Article  Google Scholar 

  • Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61:561–6.

    Article  Google Scholar 

  • Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO study. Arch Neurol. 2005;62:241–8.

    Article  Google Scholar 

  • Perez-Lloret S, Rascol O. Piribedil for the treatment of motor and non-motor symptoms of Parkinson disease. CNS Drugs. 2016;30:703–17.

    Article  CAS  PubMed  Google Scholar 

  • Perez-Lloret S, Peralta MC, Barrantes FJ. Pharmacotherapies for Parkinson’s disease symptoms related to cholinergic degeneration. Expert Opin Pharmacother. 2016;17:2405–15.

    Article  CAS  PubMed  Google Scholar 

  • Poewe W, Rascol O, Barone P, Hauser RA, Mizuno Y, Haaksma M, Salin L, Juhel N, Schapira AH, Pramipexole ER Studies Group. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology. 2011;77:759–66.

    Article  CAS  PubMed  Google Scholar 

  • Pogarell O, Gasser T, van Hilten JJ, Spieker S, Pollentier S, Meier D, Oertel WH. Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry. 2002;72:713–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rajput A, Wallkait M, Rajput AH. 18 month prospective study of amantadine for DOPA induced dyskinesias in idiopathic Parkinson’s disease. Can Neurol Sci. 1997;24:S23.

    Google Scholar 

  • Rascol O, Hauser RA, Stocchi F, Fitzer-Attas CJ, Sidi Y, Abler V, Olanow CW. Long-term effects of rasagiline and the natural history of treated Parkinson’s disease. Mov Disord. 2016;31:1489–96.

    Article  CAS  PubMed  Google Scholar 

  • Reddy P, Martinez-Martin P, Rizos A, Martin A, Faye GC, Forgacs I, Odin P, Antonini A, Chaudhuri KR. Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and nonmotor effects. Clin Neuropharmacol. 2012;35:205–7.

    Article  CAS  PubMed  Google Scholar 

  • Rizos A, Sauerbier A, Antonini A, Weintraub D, Martinez-Martin P, Kessel B, Henriksen T, Falup-Pecurariu C, Silverdale M, Durner G, Røkenes Karlsen K, Grilo M, Odin P, Chaudhuri KR. A European multicentre survey of impulse control behaviours in Parkinson’s disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol. 2016;23:1255–61.

    Article  CAS  PubMed  Google Scholar 

  • Rocha JF, Almeida L, FalcĂŁo A, Palma PN, Loureiro AI, Pinto R, Bonifácio MJ, Wright LC, Nunes T, Soares-da-Silva P. Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol. 2013;76:763–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sawada H, Oeda T, Kuno S, Nomoto M, Yamamoto K, Yamamoto M, Hisanaga K, Kawamura T. Amantadine for dyskinesias in Parkinson’s disease: a randomized controlled trial. PLoS One. 2010;5:e15298.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schapira AHV. The clinical relevance of levodopa toxicity in the treatment of Parkinson’s disease. Mov Disord. 2008;23(Suppl 3):S515–20.

    Article  PubMed  Google Scholar 

  • Schapira AH. Monoamine oxidase B inhibitors for the treatment of Parkinson’s disease: a review of symptomatic and potential disease-modifying effects. CNS Drugs. 2011;25:1061–71.

    Article  CAS  PubMed  Google Scholar 

  • Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Salin L, Juhel N, Poewe W, Pramipexole ER Studies Group. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology. 2011;77:767–74.

    Article  CAS  PubMed  Google Scholar 

  • Schapira AHV, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, Kulisevsky J, Pahwa R, Poewe W, Anand R. Safinamide as adjunct to levodopa in Parkinson’s disease patients with motor fluctuations: A 24-week randomized, double-blind, placebo-controlled trial. JAMA Neurology. 2017;74:216–224.

    Article  PubMed  Google Scholar 

  • Schrag A, Keens J, Warner J. Ropinirole for the treatment of tremor in early Parkinson’s disease. Eur J Neurol. 2002;9:253–7.

    Article  CAS  PubMed  Google Scholar 

  • Schwab RS, England AC Jr, Poskaner DC. Amantadine in the treatment of Parkinson’s disease. J Am Med Assoc. 1969;208:1163–70.

    Article  Google Scholar 

  • Sethi KD, O’Brien CF, Hammerstad JP, Adler CH, Davis TL, Taylor RL, Sanchez-Ramos J, Bertoni JM, Hauser RA. Ropinirole for the treatment of early Parkinson’s disease: a 12-month experience. Arch Neurol. 1998;55:1211–6.

    Article  CAS  PubMed  Google Scholar 

  • Stern MB, Marek KL, Friedman J, Hauser RA, LeWitt PA, Tarsy D, Olanow CW. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson’s disease patients. Mov Disord. 2004;19:916–23.

    Article  PubMed  Google Scholar 

  • Stetter H, Mayer J, Schwarz M, Wulff K. Beiträge zur Chemie der Adamantanyl-(1)-Derivate. Chem Ber. 1960;93:226–30.

    Article  CAS  Google Scholar 

  • Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68:18–27.

    Article  CAS  PubMed  Google Scholar 

  • Stocchi F, Hsu A, Khanna S, Ellenbogen A, Mahler A, Liang G, Dillmann U, Rubens R, Kell S, Gupta S. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Parkinsonism Relat Disord. 2014;20:1335–40.

    Article  PubMed  Google Scholar 

  • Talati R, Reinhart K, Baker W, White CM, Coleman CI. Pharmacologic treatment of advanced Parkinson’s disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors. Parkinsonism Relat Disord. 2009;15:500–5.

    Article  PubMed  Google Scholar 

  • Tönges L, Ceballos-Baumann A, Honig H, Storch A, Jost WH. Praktische Anwendung der kontinuierlichen Apomorphin-Pumpentherapie. Fortschr Neurol Psychiatr. 2017;85:516–35.

    Article  PubMed  Google Scholar 

  • Toth C, Brown MS, Furtado S, Suchowersky O, Zochodne D. Neuropathy as a potential complication of levodopa use in Parkinson’s disease. Mov Disord. 2008;13:1850–9.

    Article  Google Scholar 

  • Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR, Recover Study Group. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26:90–9.

    Article  PubMed  Google Scholar 

  • Vijayakumar D, Jankovic J. Drug-induced dyskinesia, Part 1: treatment of levodopa-induced dyskinesia. Drugs. 2016;76:759–77.

    Article  CAS  PubMed  Google Scholar 

  • Virmani T, Tazan S, Mazzoni P, Ford B, Greene PE. Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson’s disease. J Clin Mov Disord. 2016;3:8. https://doi.org/10.1186/s40734-016-0036-9.

    Article  PubMed  PubMed Central  Google Scholar 

  • Walker RW, Howells AR, Gray WK. The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson’s disease. Parkinsonism Relat Disord. 2011;17:27–9.

    Article  PubMed  Google Scholar 

  • Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007;68:272–6.

    Article  CAS  PubMed  Google Scholar 

  • Weil E. De l’apomorphine dans certain troubles nerveaux. Lyon Med. 1884;48:411–9.

    Google Scholar 

  • Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P, Ott E, Kloiber I, Haubenberger D, Auff E, Poewe W. Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease. Mov Disord. 2010;25:1357–63.

    Article  PubMed  Google Scholar 

  • Youdim MBH, Gross A, Finberg JP. Rasagiline [N-propargyl-1R (+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol. 2001;132:500–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zibetti M, Merola A, Artusi CA, Rizzi L, Angrisano S, Reggio D, De Angelis C, Rizzone M, Lopiano L. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease: a 7-year experience. Eur J Neurol. 2014;21:312–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Parkinson-Klinik Ortenau, Wolfach, Germany

    Wolfgang H. Jost

Authors
  1. Wolfgang H. Jost
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wolfgang H. Jost .

Editor information

Editors and Affiliations

  1. Dept Psychiatry , Psychosomatics & Psychotherapy, University of WĂĽrzburg, Medical School Clinical Neurochemistry, WĂĽrzburg, Germany

    Peter Riederer

  2. Inst fĂĽr Psychologische Medizin, Haag, Bayern, Germany

    Gerd Laux

  3. Department of Psychiatry, University of Toronto Department of Psychiatry, Toronto, ON, Canada

    Benoit Mulsant

  4. Center Translational Res Neurol Diseases, Dalian Med Uni Shanghai Inst Health Sc Center Translational Res Neurol Diseases, Dalian, China

    Weidong Le

  5. Fujita Health University School Medicine, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

Section Editor information

  1. Fujita Health University School of Medicine, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

  2. Institute of Environmental Medicine, Nagoya University, Nagoya, Aichi, Japan

    Toshiharu Nagatsu

  3. Department of Physiological Chemistry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

    Akira Nakashima

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Jost, W.H. (2020). Parkinsonian Drugs: Indications. In: Riederer, P., Laux, G., Mulsant, B., Le, W., Nagatsu, T. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_216-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56015-1_216-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56015-1

  • Online ISBN: 978-3-319-56015-1

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation